Navigation Links
Montreal researchers shed light on common juvenile cancer
Date:6/16/2010

This release is available in French.

Montreal, June 16, 2010 A team of researchers from the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral have defined for the first time the mechanism behind three cancer-causing genes in acute lymphoblastic leukemia. Published in the journal Genes and Development, the findings offer insight on the complex interaction between the genes and their contributions to leukemia, thereby providing the foundation for the design of targeted therapies.

The study was conducted by primary authors Mathieu Tremblay, Ph.D. student and Cdric Tremblay, post-doctoral fellow in the Hematopoiesis and Leukemia Laboratory at the Universit de Montral and led by corresponding author and IRIC Principal Investigator, Trang Hoang.

Acute lymphoblastic leukemia (ALL) is the most frequent childhood cancers and affects lymphocytes, the cells in the body that normally fight infections. ALL starts when a single, immature white blood cell called a "blast" develops a series of mistakes or mutations that allow it to multiply uncontrollably. Eventually, these leukemic blasts take over the lymphoid organs, the bone marrow and crowd out normal blood cells.

While extensive research has been conducted over the years to understand this type of cancer, deciphering the complex process responsible for transforming normal cells into cancerous cells remains a challenge. In this study, researchers started from the well-known basis that the interaction between two genes, SCL and LMO, is involved at the onset of a specific type of ALL, called T-cell leukemia.

"We wanted to uncover the precise mechanism behind the process that causes a normal cell to become cancerous. Our study reveals that SCL and LMO expand the pool of immature lymphocytes, which proliferate intensively under the influence of a specific signal. These SCL-LMO-primed cells then acquire mutations in a third gene, Notch1, which is known to play a role in the majority of T-ALL patients," explains Trang Hoang. "In short, the synergy between these three genes in a permissive cell is sufficient to induce leukemia."

Although chemotherapy can cure up to 80 percent of ALL in children, researchers hope to minimize the side effects by designing new therapies that specifically target cancer causing genes. "The knowledge from our study could be instrumental in the development of less invasive cancer therapies," adds Dr. Hoang.


'/>"/>

Contact: Carolyne Lord
carolyne.lord@umontreal.ca
514-343-7282
University of Montreal
Source:Eurekalert

Related medicine news :

1. UCSF Researchers Identify Regulator of Human Sperm Cells
2. Researchers find broad spectrum antiviral that fights multitude of viruses
3. University of Alberta researchers develop drug interface to save lives
4. Caregivers of ICU patients are collateral damage of critical illness, say Pitt researchers
5. Researchers fight world hunger by mapping the soybean genome
6. HIV researchers solve key puzzle after 20 years of trying
7. UC Davis researchers identify brain protein for synapse development
8. UCLA cancer researchers perform complete genomic sequencing of brain cancer cell line
9. Researchers find new way to study how enzymes repair DNA damage
10. UCLA researchers image earliest signs of Alzheimers, before symptoms appear
11. Researchers find leukemia cells metabolize fat to avoid cell death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... , ... August 17, 2017 , ... When Amy ... stretcher side nurse, she took with her a dream to make nursing education more ... Specifically, ensuring communication skills were integrated into healthcare provider education. , ...
(Date:8/17/2017)... ... August 17, 2017 , ... Brookfield, ... for healthcare, hospitality and education, is celebrating its 30th year in business this ... begun at manufacturing companies Square D, Allis Chalmers and Johnson Controls. Following his ...
(Date:8/17/2017)... ... 2017 , ... Aeroflow Healthcare today announced its placement on ... private companies. Inc. magazine ranked Aeroflow Healthcare #2450 on its annual list, showcasing ... Inc. 5000 represents the most comprehensive study of American entrepreneurial enterprises based on ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on ... plastic surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop ... that standards of male appearance are changing not only in the Asian nation, where ...
(Date:8/17/2017)... ... August 17, 2017 , ... Pot Valet is a leading provider of premium ... in the state, and soon, every state in the country, the company offers patients ... cannabis dispensary altogether. , According to Pot Valet, all California patients have ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... , Aug. 3, 2017  Opioid addiction and other ... up healthcare costs and threatening outcomes, were problems taken ... and IVD industry that support them, met this week. ... researcher said that drugs of abuse, procalcitonin and acute ... at the organization,s 69th meeting in San ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/28/2017)... --EnvoyHealth, a Diplomat company, has partnered with Compliance Meds ... a technology designed to improve patient medication adherence. ... solutions and services that help track and improve patients, ... LITE offers medication monitoring and control for patients and ... Records date and time of bottle ...
Breaking Medicine Technology: